Department of Medicinal Chemistry, University of Kansas, Lawrence, KS 66047, United States.
Bioorg Med Chem Lett. 2011 Jun 1;21(11):3232-6. doi: 10.1016/j.bmcl.2011.04.050. Epub 2011 Apr 20.
Toll-like receptor (TLR)-7 agonists show prominent Th1-biased immunostimulatory activities. A TLR7-active N(1)-(4-aminomethyl)benzyl substituted imidazoquinoline 1 served as a convenient precursor for the syntheses of isothiocyanate and maleimide derivatives for covalent attachment to free amine and thiol groups of peptides and proteins. 1 was also amenable to direct reductive amination with maltoheptaose without significant loss of activity. Covalent conjugation of the isothiocyanate derivative 2 to α-lactalbumin could be achieved under mild, non-denaturing conditions, in a controlled manner and with full preservation of antigenicity. The self-adjuvanting α-lactalbumin construct induced robust, high-affinity immunoglobulin titers in murine models. The premise of covalently decorating protein antigens with adjuvants offers the possibility of drastically reducing systemic exposure of the adjuvant, and yet eliciting strong, Th1-biased immune responses.
Toll-like 受体 (TLR)-7 激动剂表现出明显的 Th1 偏向性免疫刺激活性。一种 TLR7 活性的 N(1)-(4-氨基甲基)苄基取代的咪唑并喹啉 1 可用作方便的前体,用于合成异硫氰酸酯和马来酰亚胺衍生物,用于与肽和蛋白质的游离胺和巯基共价连接。1 还适合与麦芽七糖直接进行还原胺化,而不会显著损失活性。异硫氰酸酯衍生物 2 可以在温和、非变性的条件下,以可控的方式,完全保留抗原性,与α-乳白蛋白进行共价偶联。自佐剂的α-乳白蛋白构建体在小鼠模型中诱导出强大的、高亲和力的免疫球蛋白滴度。用佐剂共价修饰蛋白质抗原的前提提供了大幅降低佐剂全身暴露的可能性,同时引发强烈的 Th1 偏向性免疫反应。